Drugs / TDF
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05585307 Background | Oct 2022 → Feb 2024 | HIV infectious disease | Gilead Sciences | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TDF | “Non-NNRTIs, examples: ABC/DTG/3TC; DTG plus (TAF or TDF) plus (FTC or 3TC)” NCT05585307 ↗ |
| Route | Oral | “Antiretroviral therapy, administered orally” NCT05585307 ↗ |